RNA-sequencing of acute promyelocytic leukemia primary blasts reveals novel molecular biomarkers of early death events

References

• Lo-Coco F, Di Donato L, Schlenk RF. Targeted therapy alone for acute promyelocytic leukemia. N Engl J Med. 2016;374(12):1197–1198.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017;35(6):605–612.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128–1134.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood. 2009;113(4):775–783.
   PubMed Web of Science ®Google Scholar
• Rahme R, Thomas X, Recher C, et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12):2422–2424.
   PubMed Web of Science ®Google Scholar
• McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica. 2012;97(1):133–136.
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248–1254.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–1891.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103(4):1237–1243.
   PubMed Web of Science ®Google Scholar
• Altman JK, Rademaker A, Cull E, et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res. 2013;37(9):1004–1009.
   PubMed Web of Science ®Google Scholar
• Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med. 1999;340(13):994–1004.
   PubMed Web of Science ®Google Scholar
• O'Connell PA, Surette AP, Liwski RS, et al. S100A10 regulates plasminogen-dependent macrophage invasion. Blood. 2010;116(7):1136–1146.
   PubMed Web of Science ®Google Scholar
• Huang D, Yang Y, Sun J, et al. Annexin A2-S100A10 heterotetramer is upregulated by PML/RARα fusion protein and promotes plasminogen-dependent fibrinolysis and matrix invasion in acute promyelocytic leukemia. Front Med. 2017;11(3):410–422.
   PubMed Web of Science ®Google Scholar
• Tapiovaara H, Matikainen S, Hurme M, et al. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood. 1994;83(7):1883–1891.
   PubMed Web of Science ®Google Scholar
• Choudhry A, DeLoughery TG. Bleeding and thrombosis in acute promyelocytic leukemia. Am J Hematol. 2012;87(6):596–603.
   PubMed Web of Science ®Google Scholar
• Nowak D, Klaumuenzer M, Hanfstein B, et al. SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3. Genes Chromosom Cancer. 2012;51(8):756–767.
   PubMed Web of Science ®Google Scholar
• Hecht A, Nowak D, Nowak V, et al. A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia. Leuk Res. 2015;39(11):1172–1177.
   Web of Science ®Google Scholar
• Lavallee VP, Chagraoui J, MacRae T, et al. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia. 2018;32(6):1349–1357.
   PubMed Web of Science ®Google Scholar
• Lengfelder E, Gorlich D, Nowak D, et al. Frontline therapy of acute promyelocytic leukemia: randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines. Eur J Haematol. 2018;100(2):154–162.
   PubMed Web of Science ®Google Scholar
• Team RRD. A: Language and environment for statistical computing; 2018. https://www.R-project.org
   Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci Usa. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Nicorici D, Şatalan M, Edgren H, et al. FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data. bioRxiv. 2014. DOI:10.1101/011650.
   Google Scholar
• Paulson K, Serebrin A, Lambert P, et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014;166(5):660–666.
   PubMed Web of Science ®Google Scholar
• Lagasse E, Clerc RG. Cloning and expression of two human genes encoding calcium-binding proteins that are regulated during myeloid differentiation. Mol Cell Biol. 1988;8(6):2402–2410.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Nicolas E, Ramus C, Berthier S, et al. Expression of S100A8 in leukemic cells predicts poor survival in de novo AML patients. Leukemia. 2011;25(1):57–65.
   PubMed Web of Science ®Google Scholar
• Pass HI, Goparaju C. Fibulin-3 as a biomarker for pleural mesothelioma. N Engl J Med. 2013;368(2):190.
   PubMedGoogle Scholar
• Vijil C, Hermansson C, Jeppsson A, et al. Arachidonate 15-lipoxygenase enzyme products increase platelet aggregation and thrombin generation. PLoS One. 2014;9(2):e88546.
   PubMed Web of Science ®Google Scholar
• Krezel A, Hao Q, Maret W. The zinc/thiolate redox biochemistry of metallothionein and the control of zinc ion fluctuations in cell signaling. Arch Biochem Biophys. 2007;463(2):188–200.
   PubMed Web of Science ®Google Scholar
• Hirako N, Nakano H, Takahashi S. A PU.1 suppressive target gene, metallothionein 1G, inhibits retinoic acid-induced NB4 cell differentiation. PLoS One. 2014;9(7):e103282.
   PubMed Web of Science ®Google Scholar
• Kumar A, Kankainen M, Parsons A, et al. The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. BMC Genomics. 2017;18(1):629.
   PubMedGoogle Scholar
• Tyner JW, Tognon CE, Bottomly D, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526–531.
   PubMed Web of Science ®Google Scholar
• Locher IJ, Arindrarto W, Borràs DM, et al. Fusion transcripts without corresponding cytogenetic abnormalities in acute myeloid leukemia: implications for AML pathogenesis. Blood. 2017;130(Suppl 1):2703.
   Google Scholar